Drugs / RNK001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03539406 | Jun 2019 → May 2023 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RNK001 | “We present the first-in-human study exploiting the safety of the NK cell product designated RNK001, derived ex vivo from umbilical cord blood-derived hematopoietic stem and...” PMID 41289795 ↗ Nov 2025 |